87 Randomized phase III trial of mitomycin plus vindesine and cisplatin versus vinorelbine and cisplatin in stage III–IV non-small cell lung cancer: A Southern Italy Oncology Group study (G.O.I.M.)
Vittorio Gebbia(Università degli Studi di Enna Kore), Gianluca Colucci, Ernesto Durini(Ito Hospital), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), D. Galeta, N. Gebbia, A. Testa(Istituto di Fisiologia Clinica), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234